CLINICAL STUDY: HEART FAILURE
The prevalence of treatable left ventricular systolic dysfunction in patients who present with noncardiac vascular episodes
A case-control study
Robert Kelly, MD, MRCPI*,
Anthony Staines, PhD, MRCPI||,
Ron MacWalter, FRCP ,
Peter Stonebridge, MCh, FRCS ,
Hugh Tunstall-Pedoe, MD, FRCP and
Allan D. Struthers, MD, FRCP*,*
* Department of Clinical Pharmacology, University of Dundee and Medical School, Ninewells Hospital, Dundee, Scotland, United Kingdom
Department of Medicine, University of Dundee and Medical School, Ninewells Hospital, Dundee, Scotland, United Kingdom
Department of Surgery, University of Dundee and Medical School, Ninewells Hospital, Dundee, Scotland, United Kingdom
Cardiovascular Epidemiology Unit, University of Dundee and Medical School, Ninewells Hospital, Dundee, Scotland, United Kingdom
|| Department of Public Health Medicine, University College, Dublin, Ireland
Manuscript received May 8, 2001;
revised manuscript received September 21, 2001,
accepted October 19, 2001.
* Reprint requests and correspondence: Prof. Allan D. Struthers, Department of Clinical Pharmacology, Ninewells Hospital, Dundee, Scotland DD1 9SY, United Kingdom. a.d.struthers{at}dundee.ac.uk
OBJECTIVES: We sought to determine the prevalence of treatable left ventricular (LV) systolic dysfunction (LVSD) in patients who present with their first noncardiac vascular episode.
BACKGROUND: Screening for LV dysfunction in patients who present with their first stroke (cerebrovascular accident), their first transient ischemic attack (TIA) or their first manifestation of peripheral vascular disease (PVD) may represent a golden opportunity to identify treatable LV dysfunction, and so their known high incidence of sudden cardiac death may be reduced.
METHODS: Participating in this study were 522 (75%) of 700 consecutive patients (302 patients with stroke, TIA or PVD and 220 age- and gender-matched control subjects). Each underwent a full clinical assessment, 12-lead electrocardiography and two-dimensional echocardiography. Left ventricular dysfunction was defined as LV ejection fraction 40%.
RESULTS: Seventy-two (28%) patients with vascular disease and 11 (5.5%) control subjects were found to have LVSD. Twenty-six (28%) stroke patients, 22 (26%) patients with TIA and 24 (31%) patients with PVD had LVSD. Left ventricular systolic dysfunction was symptomatic in 44% of patients and in 35% of control subjects.
CONCLUSIONS: Left ventricular systolic dysfunction is five times more common among patients with stroke, TIA and PVD than among age- and gender-matched control subjects. Asymptomatic LVSD is more common than symptomatic LVSD in these patients. These findings suggest that routine screening of all patients with noncardiac vascular episodes for LVSD should now be considered. Future studies should investigate whether identifying and treating LVSD in these patients would reduce their known high rate of cardiac death.
|
Abbreviations and Acronyms
| | ACE | | angiotensin-converting enzyme | | CI | | confidence interval | | ECG | | electrocardiogram | | HOPE | | Heart Outcomes Prevention Evaluation study | | ICD | | implantable cardioverter-defibrillator | | IHD | | ischemic heart disease | | LV | | left ventricular | | LVEF | | left ventricular ejection fraction | | LVSD | | left ventricular systolic dysfunction | | MI | | myocardial infarction | | PVD | | peripheral vascular disease | | TIA | | transient ischemic attack |
|
This article has been cited by other articles:

|
 |

|
 |
 
A. G. Hays, R. L. Sacco, T. Rundek, R. R. Sciacca, Z. Jin, R. Liu, S. Homma, and M. R. Di Tullio
Left Ventricular Systolic Dysfunction and the Risk of Ischemic Stroke in a Multiethnic Population
Stroke,
July 1, 2006;
37(7):
1715 - 1719.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. I.W. Galasko, A. Lahiri, S. C. Barnes, P. Collinson, and R. Senior
What is the normal range for N-terminal pro-brain natriuretic peptide? How well does this normal range screen for cardiovascular disease?
Eur. Heart J.,
November 1, 2005;
26(21):
2269 - 2276.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Patel, M. Woodward, D. J. Campbell, D. R. Sullivan, S. Colman, J. Chalmers, B. Neal, and S. MacMahon
Plasma lipids predict myocardial infarction, but not stroke, in patients with established cerebrovascular disease
Eur. Heart J.,
September 2, 2005;
26(18):
1910 - 1915.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. A. Heidenreich, M. A. Gubens, G. C. Fonarow, M. A. Konstam, L. W. Stevenson, and P. G. Shekelle
Cost-effectiveness of screening with B-type natriuretic peptide to identify patients with reduced left ventricular ejection fraction
J. Am. Coll. Cardiol.,
March 17, 2004;
43(6):
1019 - 1026.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Fox
Poststroke patients: implications for the cardiologist
Eur. Heart J. Suppl.,
July 1, 2003;
5(suppl_E):
E4 - E10.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
PROGRESS Collaborative Group
Effects of a perindopril-based blood pressure lowering regimen on cardiac outcomes among patients with cerebrovascular disease
Eur. Heart J.,
March 1, 2003;
24(5):
475 - 484.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|